TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31323454

Group type: EXPERIMENTAL
Intervention: CADScor®System (Acarix A/S, Denmark)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 3T cardiac magnetic resonance imaging (3T CMRI)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 82rubidium positron emission tomography (82Rb-PET)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: CT-derived fractional flow reserve (FFRCT)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 2000
Study: 28007635

Group type: EXPERIMENTAL
Intervention: Integrated pharmaceutical care at a psychosocial intervention
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study: 26653621

Group type: EXPERIMENTAL
Intervention: Renal artery stent placement plus medical therapy
Number of subjects: 947

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 947
Study: 22485012

Group type: EXPERIMENTAL
Intervention: Fotonovela
Number of subjects: 157

Group type: COMPARATOR
Intervention: Text pamphlet
Number of subjects: 157
Study: 22207522

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC) (2 × 1) for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Brimonidine/timolol fixed combination (BTFC) (2 × 1) for 4 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both DTFC and BTFC
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 42
Study: 19630975

Group type: EXPERIMENTAL
Intervention: Protocolized treatment based on active and passive joint repositioning, stabilization exercises, stretching of the periarticular shoulder muscles and postural reeducation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocolized treatment with the addition of dry needling applied to active MTrPs.
Number of subjects: 0
Study: 16485577

Group type: EXPERIMENTAL
Intervention: Withholding levothyroxine before 131I therapy (Group G1.1)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Withholding levothyroxine before 131I therapy (Group G1.2)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Administration of recombinant human thyrotropin without stopping levothyroxine (Group G2)
Number of subjects: 163
Study: 15277271

Group type: EXPERIMENTAL
Intervention: BAY 38-3441 at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600 mg/m2/day for 1 day every 3 weeks (single-dose schedule)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: BAY 38-3441 at doses of 126, 189, 246, 320 and 416 mg/m2/day once daily for three consecutive days every 3 weeks (3-day schedule)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: BAY 38-3441
Number of subjects: 81
Study: 11160951

Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 mg/day target maintenance dosage, adjusted from 100 to 500 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Valproate (20 mg/kg/day target maintenance dosage, adjusted from 10 to 60 mg/kg/day)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 133

Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 133
Study: 9037288

Group type: EXPERIMENTAL
Intervention: Sachse urethrotomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Guillemin's technique (double direct-optical endoscopic urethrotomy plus transurethral resection of scar tissues)
Number of subjects: 80
Study: 8287887

Group type: EXPERIMENTAL
Intervention: Orchiectomy + Cyproterone Acetate (CPA)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Orchiectomy + Placebo
Number of subjects: 294
Study: 2887431

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31529097

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 18
Study: 30519590

Group type: EXPERIMENTAL
Intervention: Fast administration of 500ml balanced crystalloid fluid challenge (5-10 minutes)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Slow administration of 500ml balanced crystalloid fluid challenge (20-30 minutes)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fast administration
Number of subjects: 66

Group type: COMPARATOR
Intervention: Slow administration
Number of subjects: 66
Study: 27716095

Group type: EXPERIMENTAL
Intervention: Elderly Persons in the Risk Zone (EPRZ) health-promoting programme
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 459
Study: 24126707

Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 582

Group type: COMPARATOR
Intervention: methadone
Number of subjects: 582
Study: 22237884

Group type: EXPERIMENTAL
Intervention: Prebiotic-containing formula (PRE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control formula (CON)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Breastfed infants (BF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Formula-fed infants (FF)
Number of subjects: 100
Study: 20831535

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg (RAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg (EAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clarithromycin-sensitive strains
Number of subjects: 0
Study: 19024254

Group type: EXPERIMENTAL
Intervention: 1% CHX varnish applied once (Group A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 1% CHX varnish applied once daily for 3 consecutive days (Group B)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 1% CHX varnish applied three times with 4 days interval (Group C)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo varnish applied once daily for 3 consecutive days (Group D)
Number of subjects: 55
Study: 16458191

Group type: EXPERIMENTAL
Intervention: High phenolic content olive oil (366 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate phenolic content olive oil (164 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low phenolic content olive oil (2.7 mg/kg)
Number of subjects: 12
Study: 15152880

Group type: EXPERIMENTAL
Intervention: Behavioral Construct Tailoring (BCT)
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Culturally Relevant Tailoring (CRT)
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Combined (BCT + CRT)
Number of subjects: 1227
Study: 11309548

Group type: EXPERIMENTAL
Intervention: Basiliximab (40 mg total: 20 mg on days 0 and 4)
Number of subjects: 184
Study: 9339962

Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists, antacids, sucralfate, pirenzepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: prostaglandins, omeprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: optimised resuscitation and ICU regime
Number of subjects: 0
Study: 8373288

Group type: EXPERIMENTAL
Intervention: Double method wash
Number of subjects: 195

Group type: COMPARATOR
Intervention: Centrifuge method wash
Number of subjects: 195
Study: 3728212

Group type: EXPERIMENTAL
Intervention: Terbutaline (intravenous administration for 5 hours)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Isoprenaline (intravenous administration for 5 hours)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Terbutaline (oral administration for 24 days)
Number of subjects: 5
Study: 30834639

Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agent first
Number of subjects: 562

Group type: COMPARATOR
Intervention: Sedative agent first
Number of subjects: 562
Study: 29652786

Group type: EXPERIMENTAL
Intervention: Surgery (standard decompressive laminectomy with or without fusion)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 69
Study: 25565290

Group type: EXPERIMENTAL
Intervention: GP-led integrated diabetes care
Number of subjects: 30
Study: 25289885

Group type: EXPERIMENTAL
Intervention: 1000-m cycling time trial at 6 pm
Number of subjects: 9

Group type: COMPARATOR
Intervention: 1000-m cycling time trial at 8 am
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hormonal response in the morning
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hormonal response in the evening
Number of subjects: 9

Group type: COMPARATOR
Intervention: Plasma glucose in the morning
Number of subjects: 9

Group type: COMPARATOR
Intervention: Norepinephrine response in the morning
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Norepinephrine response in the evening
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Muscle recruitment measured by electromyography
Number of subjects: 9
Study: 22301799

Group type: EXPERIMENTAL
Intervention: Tissue-tolerable plasma (TTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Octenidine hydrochloride with 2-phenoxyethanol
Number of subjects: 0
Study: 20140897

Group type: EXPERIMENTAL
Intervention: 50 g isomaltulose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 g sucrose
Number of subjects: 24

Group type: COMPARATOR
Intervention: water control
Number of subjects: 24
Study: 17650803

Group type: EXPERIMENTAL
Intervention: RT combined with oral TCM from the start of RT till 5 weeks after RT
Number of subjects: 195

Group type: COMPARATOR
Intervention: RT alone for 7 weeks
Number of subjects: 195
Study: 15249999

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) for cup placement in THA
Number of subjects: 185

Group type: COMPARATOR
Intervention: Free-hand cup placement in THA
Number of subjects: 185
Study: 12462555

Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.1 microg/kg min)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 microg/kg min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 25
Study: 9430135

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (amino acid mixture devoid of tryptophan)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo control (amino acid mixture containing 2.3 g of tryptophan)
Number of subjects: 12
Study: 7655769

Group type: EXPERIMENTAL
Intervention: Profinal (600 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Brufen (600 mg)
Number of subjects: 18
Study: 2571061

Group type: EXPERIMENTAL
Intervention: OM756 alpha 10 mg propranolol 'Inderal' tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Generic 10 mg propranolol tablet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Generic placebo
Number of subjects: 12
Study: 1099176

Group type: EXPERIMENTAL
Intervention: 4000 mg of ascorbic acid administered 27 and 3 hours prior to assessment
Number of subjects: 18

Group type: COMPARATOR
Intervention: 50 mg of ascorbic acid administered in the same manner
Number of subjects: 18
Study: 29985968

Group type: EXPERIMENTAL
Intervention: Girls on the Move (GOTM) intervention
Number of subjects: 1519

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1519
Study: 27940187

Group type: EXPERIMENTAL
Intervention: Telephone-assisted DESTRESS intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone monitoring only (Control)
Number of subjects: 0
Study: 25982993

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 10
Study: 23065145

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir (TFV)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Daily topical tenofovir (TFV) vaginal gel
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both oral tablet and vaginal gel
Number of subjects: 144

Group type: COMPARATOR
Intervention: Oral tablet
Number of subjects: 144

Group type: COMPARATOR
Intervention: Vaginal gel
Number of subjects: 144
Study: 21617526

Group type: EXPERIMENTAL
Intervention: Standard endotracheal intubation (ETI)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 42
Study: 19877969

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 351

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 351
Study: 16449754

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor treatment (AD+ChEI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No Cholinesterase inhibitor treatment (AD‐ChEI)
Number of subjects: 28
Study: 15339677

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Autologous SCT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Adverse cytogenetics and white blood cell count ≥20 yen 10^9/L at diagnosis
Number of subjects: 200
Study: 11278221

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 132

Group type: COMPARATOR
Intervention: IVF in unstimulated cycles
Number of subjects: 132
Study: 9567611

Group type: EXPERIMENTAL
Intervention: Ventilator circuit change every 5 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ventilator circuit change every 10 days
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups (5 days and 10 days)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patients who developed airway infection
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Patients who did not develop airway infection
Number of subjects: 78
Study: 8187315

Group type: EXPERIMENTAL
Intervention: High insulin infusion (60 mU/kg/h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low insulin infusion (15 mU/kg/h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both insulin levels
Number of subjects: 8
Study: 2835977

Group type: EXPERIMENTAL
Intervention: Diet 1 (40% energy as carbohydrate, 10 g dietary fibre)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Diet 2 (40% energy as carbohydrate, 52 g dietary fibre)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Diet 3 (60% energy as carbohydrate, 84 g dietary fibre)
Number of subjects: 29
Study: 30167741

Group type: EXPERIMENTAL
Intervention: Percutaneous pedicle screw fixation (PPSF)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open pedicle screw fixation (OPSF)
Number of subjects: 46
Study: 31568799

Group type: EXPERIMENTAL
Intervention: Oral maribavir treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 120

Group type: COMPARATOR
Intervention: Maribavir
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of F342Y and H411Y
Number of subjects: 120
Study: 28787340

Group type: EXPERIMENTAL
Intervention: Automatic cuff pressure control based on subglottic CO2 levels
Number of subjects: 64

Group type: COMPARATOR
Intervention: Manual cuff pressure management using a manometer 3 times/d
Number of subjects: 64
Study: 26085289

Group type: EXPERIMENTAL
Intervention: Forced nocturnal awakenings (FA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Restricted sleep opportunity (RSO)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Uninterrupted sleep (US)
Number of subjects: 62
Study: 23835011

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT) sessions three times per week for 6 weeks (n = 12)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Weekly friendly visits (FV) (n = 7)
Number of subjects: 19
Study: 20655712

Group type: EXPERIMENTAL
Intervention: Dendrobium candidum extract (DCEL) administered orally for 1 week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 19450062

Group type: EXPERIMENTAL
Intervention: Solifenacin (5 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 16439929

Group type: EXPERIMENTAL
Intervention: wallet-sized referral card
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 20-minute nurse case management protocol
Number of subjects: 360
Study: 12740260

Group type: EXPERIMENTAL
Intervention: Acetazolamide, 250 mg bid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 30 mg bid
Number of subjects: 12
Study: 10850938

Group type: EXPERIMENTAL
Intervention: Early enteral feeding with immune-enhancing diet (Impact with fiber) initiated < 72 hours after trauma
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed enteral feeding with immune-enhancing diet (Impact with fiber) administered after gastric ileus resolved
Number of subjects: 30
Study: 9542722

Group type: EXPERIMENTAL
Intervention: Low protein breakfast
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low fat breakfast
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low carbohydrate breakfast
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Standard breakfast
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 17
Study: 8380508

Group type: EXPERIMENTAL
Intervention: OKT3 for 10 days (20 patients) commencing within 24‐48 hr of transplantation
Number of subjects: 41

Group type: COMPARATOR
Intervention: ATGAM for 8 days (21 patients) commencing on the day of transplantation
Number of subjects: 41
Study: 3706828

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 14
Study: 31906840

Group type: EXPERIMENTAL
Intervention: Vitamin D2 and calcium carbonate supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (only ART)
Number of subjects: 18
Study: 29658501

Group type: EXPERIMENTAL
Intervention: Extended release implantable naltrexone
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Oral naltrexone
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo (oral and implant)
Number of subjects: 306
Study: 27956679

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 2924

Group type: COMPARATOR
Intervention: No nitrous oxide
Number of subjects: 2924

Group type: EXPERIMENTAL
Intervention: Nitrous oxide in Asian patients
Number of subjects: 2924

Group type: EXPERIMENTAL
Intervention: Nitrous oxide with gene polymorphism
Number of subjects: 2924
Study: 24606117

Group type: EXPERIMENTAL
Intervention: Sublingual asenapine 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22371302

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (0.65 g/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-alcoholic placebo beverage
Number of subjects: 64
Study: 20886804

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 3058
Study: 18801887

Group type: EXPERIMENTAL
Intervention: Adiponectin concentrations (highest quintile > 9.8 microg/mL)
Number of subjects: 311
Study: 16207605

Group type: EXPERIMENTAL
Intervention: Sustained-release nitrendipine microspheres
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel pH-dependent gradient-release delivery system for nitrendipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Domestic commercial nitrendipine tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baypress nitrendipine tablets
Number of subjects: 0
Study: 12648592

Group type: EXPERIMENTAL
Intervention: Complete surgical staging including bilateral salpingo‐oophorectomy, hysterectomy, omentectomy, and pelvic and para‐aortic lymphadenectomy, followed by paclitaxel and carboplatin chemotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cisplatin‐based chemotherapy following bilateral salpingo‐oophorectomy, hysterectomy, and omentectomy without lymphadenectomy
Number of subjects: 20
Study: 11872915

Group type: EXPERIMENTAL
Intervention: Emergent use of anticoagulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin or other rapidly acting anticoagulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early anticoagulation
Number of subjects: 0
Study: 9853554

Group type: EXPERIMENTAL
Intervention: PPI + TM group (10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PPI group (10 patients)
Number of subjects: 20
Study: 7648234

Group type: COMPARATOR
Intervention: Simvastatin 20 mg nocte
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bezafibrate Slow Release (SR) 400 mg mane
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined bezafibrate and simvastatin therapy
Number of subjects: 49
Study: 2808974

Group type: EXPERIMENTAL
Intervention: Angioplasty of right coronary artery occlusions
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Angioplasty of left anterior descending artery occlusions
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Follow-up catheterization at 1 week for right coronary artery occlusions
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Follow-up catheterization at 1 week for left anterior descending artery occlusions
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Angioplasty complications for right coronary artery occlusions
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Angioplasty complications for left anterior descending artery occlusions
Number of subjects: 83
Study: 1178023

Group type: EXPERIMENTAL
Intervention: Low anti-HBs titer immune-serum globulin
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Intermediate high anti-HBs titer immune-serum globulin
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: High anti-HBs titer immune-serum globulin
Number of subjects: 712

Group type: COMPARATOR
Intervention: Control group (anti-HBs negative)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Anti-HBs positive workers
Number of subjects: 712
Study: 31024653

Group type: EXPERIMENTAL
Intervention: Flipped classroom curriculum with MKSAP readings and weekly case discussions
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual teaching (Control group)
Number of subjects: 98
Study: 27155890

Group type: EXPERIMENTAL
Intervention: LM25
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: LM50
Number of subjects: 403
Study: 25994819

Group type: EXPERIMENTAL
Intervention: Adalimumab + Methotrexate (ADA + MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (MTX or ADA)
Number of subjects: 0
Study: 23750860

Group type: EXPERIMENTAL
Intervention: Modular CBT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 40